Oct 11, 2019
Shionogi enters into a new license agreement and research collaboration for the treatment of mycobacterial diseases with Hsiri Therapeutics, Inc.
Jun 24, 2019
Shionogi Concludes Licensing Agreements with Eddingpharm for Lusutrombopag, a Thrombopoietin Receptor Agonist
Dec 05, 2018
Vast Therapeutics Announces Series A Funding
Jun 06, 2018
Shionogi enters into a license and research collaboration for the treatment of mycobacterial diseases with Hsiri Therapeutics, Inc.
Jan 05, 2018
PharmaIN and Shionogi Announce Collaboration and $17M Securities Purchase Agreements
Oct 05, 2017
Shionogi To Present S-033188 Phase 3 CAPSTONE-1 Study Results For Treatment Of Influenza At IDWeek 2017
Oct 04, 2017
Shionogi Presents Positive Clinical Efficacy Trial Results And In Vitro Data On Cefiderocol, At IDWeek 2017
Sep 28, 2017
Shionogi To Highlight Research On Cefiderocol (S-649266), A Siderophore Cephalosporin, And S-033188, A Cap-Dependent Endonuclease Inhibitor For Treatment Of Influenza, At IDWeek 2017
Sep 25, 2017
Shionogi Announces Results for Lusutrombopag (S-888711) Phase 3 Study (L-PLUS2) for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures
Jul 24, 2017
Shionogi Announces Positive Top-Line Results for S-033188 Phase 3 Study (CAPSTONE-1) in Otherwise Healthy Influenza Patients
Jun 01, 2017
Further Evidence Supports Cefiderocol Activity Against MDR Gram-Negative Pathogens: Data Presented at the American Society for Microbiology Microbe (ASM) Meeting